Research programme: oral and respiratory biological therapeutics - Cyclo Therapeutics
Latest Information Update: 01 Jan 2024
At a glance
- Originator Applied Molecular Transport
- Developer Cyclo Therapeutics
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Unspecified
Most Recent Events
- 27 Dec 2023 Applied Molecular Transport has merged with Cyclo Therapeutics to form Cyclo Therapeutics
- 29 Mar 2023 Research programme: oral and respiratory biological therapeutics - Applied Molecular Transport is available for licensing as of 27 Mar 2023. www.appliedmt.com
- 27 Mar 2023 Suspended - Preclinical for Unspecified in USA (Inhalation)